A multicenter, open-label, dose-escalation clinical trial to evaluate the safety of viral-specific T-cell (VST) therapy in the treatment of refractory viral infections after allogeneic hematopoietic stem cell transplantation (ALLOVISTA).

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517696-21-01

Acronym

2020/ABM/01/00125

Enrollment

Registered

2025-04-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant viral infections caused by cytomegalovirus (CMV) in adult patients after allogeneic hematopoietic stem cell transplantation.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026